Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DR26FGGP9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,251
Award facts
- Contract value 100% obligated
- $4,251.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,251.48 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The delivery order, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, represents a firm fixed-price contract with no set-aside designation. This award falls under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply solutions to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's role as a prime vendor contractor positions the company as a critical supplier within the federal military medical supply chain. The company's extensive product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, supporting diverse therapeutic requirements across Department of Defense healthcare operations globally. The PPV-G GEN V contract, designated SPE2DR and valued at $499,999,999 with a completion date of December 31, 2036, includes a 30-month base period and three 30-month option periods, enabling the Defense Logistics Agency to issue firm fixed-price delivery orders such as this one to meet recurring medical supply needs across the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FGGP9?
SPE2DR26FGGP9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FGGP9 worth?
The government has obligated $4,251 on SPE2DR26FGGP9.
Is contract SPE2DR26FGGP9 an order under another contract?
Yes. SPE2DR26FGGP9 is a delivery order under SPE2DR25D9349, an indefinite delivery contract.
Was contract SPE2DR26FGGP9 competed?
The extent of competition for SPE2DR26FGGP9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award